Scotiabank Initiates Coverage On Mirati Therapeutics with Sector Underperform Rating, Announces Price Target of $20
Portfolio Pulse from richadhand@benzinga.com
Scotiabank analyst George Farmer has initiated coverage on Mirati Therapeutics (NASDAQ:MRTX) with a Sector Underperform rating and a price target of $20.
July 27, 2023 | 1:39 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Scotiabank has initiated coverage on Mirati Therapeutics with a Sector Underperform rating and a price target of $20, which may negatively impact the stock's performance.
The underperform rating from Scotiabank indicates that the analyst expects Mirati Therapeutics to do worse than the average market performance. This could lead to a decrease in the stock's price. The price target of $20 also suggests that the analyst believes the stock is currently overvalued, which could further drive down the price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100